Losartan Potassium Tablet, Film Coated
Product Images NDC 71335-0262

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71335-0262). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713350262)

This is a description of a medication named Losartan. It is a white, round 50mg tablet manufactured by Zhejiang Huahai Pharma Co Ltd. It is meant to be kept out of reach of children and stored at room temperature. The medication container should be stored at a temperature between 20°C and 25°C. The container contains thirty tablets and is marked with a specific expiration date and a National Drug Code of 7133502621 04238301523487.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

FDA Label Image

Figure 1 (Spl Image2 Figure1)

This text shows the comparison between Atenolol and Losartan Potassium in terms of their effectiveness in reducing the risk of primary endpoint in patients. The results show that Losartan Potassium has an adjusted risk reduction of 13%, with a p-value of 0.021. The graph shows the study month timeline up to 66 months.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

This is a comparison between Atenolol and Losartan Potassium in reducing the risk of fatal or non-fatal stroke, where Losartan Potassium showed a 25% reduction in risk compared to Atenolol. The provided chart shows the percentage of patients with fatal or non-fatal stroke over a span of 66 study months.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

The text describes a table (Figure 3) showing the number of primary composite stroke events and hazard ratios for different subgroups (age, gender, race, ISH status, diabetes status, and history of CVD) in a study comparing the effectiveness of Losartan Potassium and Atenolol in preventing stroke. The table has symbols proportional to the sample size, and the results are adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy. The text also includes a note explaining that "Other" category includes Asian, Hispanic, Asiatic, Multi-race, Indian, Native American, European.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

This is a chart showing the percentage of patients with event (presumably a medical event) over a period of 48 months. The data compares the effects of Losartan Potassium to Placebo. Losartan Potassium treatment has shown a 16.1% risk reduction in patients with events. The significance level of this result is p=0.022.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.